Integra LifeSciences v. HyperBranch Medical Technology

Cooley successfully defended HyperBranch Medical Technology against a patent infringement lawsuit filed by a competitor, Integra LifeSciences.

After a two-week trial in Delaware federal district court, a jury found in favor of HyperBranch on all claims and defenses.

The lawsuit, filed in 2015 just two months after HyperBranch launched its Adherus AutoSpray Dural Sealant product in the United States, originally contended that HyperBranch willfully infringed 109 claims in six patents through its manufacture, use and sale of its Adherus products. Integra also filed with its complaint a motion for a preliminary injunction asking the Court to enjoin HyperBranch from making and selling the accused Adherus products during the pendency of the case.

HyperBranch defeated Integra’s preliminary injunction motion in 2016 and continued to score victories throughout the subsequent litigation. After hearing six days of testimony from witnesses and viewing numerous exhibits admitted into evidence, the jury unanimously determined that the company did not infringe any of the remaining asserted patent claims, and that all of those claims are invalid.

HyperBranch is a medical technology company focused on delivering superior patient and physician experiences through products designed to minimize post-surgical complications.

Cooley advised with a team including Jon Graves (Picture), Adam Pivovar, Stephen Crenshaw, James Hughes, Lisa Schwier, Naina Soni, Orion Armon, Joseph Van Tassel, Nicholas Lockhart and Sean Newsam.

Involved fees earner: Jon Graves – Cooley LLP; Adam Pivovar – Cooley LLP; Stephen Crenshaw – Cooley LLP; James Hughes – Cooley LLP; Lisa Schwier – Cooley LLP; Naina Soni – Cooley LLP; Orion Armon – Cooley LLP; Joseph Van Tassel – Cooley LLP; Nicholas Lockhart – Cooley LLP;

Law Firms: Cooley LLP;

Clients: HyperBranch Medical Technology, Inc.;

Author: Ambrogio Visconti